PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. Electronic address: see2132@cumc.columbia.edu.\', \'University of Pittsburgh; Department of Neurology; Pittsburgh, PA, USA.\', \'Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA.\', \'The Multiple Sclerosis Center of Northeastern New York; Latham, NY, USA.\', \'Yale University School of Medicine; Department of Neurology; New Haven, CT, USA.\', \'University of Pennsylvania School of Medicine; Department of Neurology; Philadelphia, PA, USA.\', \'State University of New York at Buffalo; Department of Neurology; Buffalo, NY, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2211-0348(21)00699-410.1016/j.msard.2021.103433
?:doi
?:hasPublicationType
?:journal
  • Multiple sclerosis and related disorders
is ?:pmid of
?:pmid
?:pmid
  • 34923427
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.123
?:rankingScore_hIndex
  • 18
is ?:relation_isRelatedTo_publication of
?:title
  • Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all